AZ divests Movantik rights to RedHill
The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances.
Read Moreby Anna Smith | Feb 25, 2020 | News | 0
The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances.
Read Moreby Selina McKee | Feb 15, 2018 | News | 0
Bristol-Myers Squibb and Nektar Therapeutics have signed a deal to develop and commercialise the latter’s lead immuno-oncology programme, NKTR-214, in combination with other anticancer therapies, on the back of the success of a previous clinical trials pact.
Read Moreby Selina McKee | Nov 24, 2017 | News | 0
Bayer and Nektar Therapeutics’ experimental inhaled antibiotic has failed to hit key targets assessing its effect on survival in patients with Gram-negative pneumonia.
Read Moreby Selina McKee | Jul 25, 2017 | News | 0
Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million.
Read Moreby Selina McKee | Sep 28, 2016 | News | 0
Bristol-Myers Squibb has signed a clinical trials pact with Nektar Therapeutics that will test a combination of the firms’ immunotherapy drugs across a range of cancer indications.
Read More
PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
